Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurodegeneration Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NUAK1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NUAK1 Active Kinase Domain / Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. |
View NUAK1 Products |
| Gene Delivery | NUAK1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. |
View NUAK1 Products |
| Benchmark Ab | Anti-NUAK1 Recombinant Antibody Recombinant positive control for Western Blot and ELISA assays. |
View NUAK1 Products |
| Validator | NUAK1 siRNA Set For target knockdown verification and specificity profiling. |
View NUAK1 Products |
| Related Target A | NUAK2 High-homology family member required for kinase selectivity counter-screening. |
View NUAK2 Products |
| Related Target B | USP9X Deubiquitinase that stabilizes NUAK1; critical node in the NUAK1 degradation pathway. |
View USP9X Products |
| Related Target C | MAPT Tau protein; downstream substrate of NUAK1 implicated in Alzheimer's disease pathology. |
View MAPT Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity against high-homology NUAK2 | Human NUAK1 and NUAK2 ortholog proteins available with >95% purity for robust comparative kinase profiling. |
| Intracellular target engagement validation | Lentivirus-based full-length ORF delivery to establish stable cell lines for cellular phosphorylation assays. |
| Lack of specific controls | Sequence-verified recombinant positive control antibodies and validated siRNA sets included for knockdown verification. |
Live NUAK1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NUAK1 therapeutics is intensifying, with major players shifting focus from traditional non-specific kinase inhibitors to highly selective small molecule inhibitors. As first-generation therapies reach the clinic, the next wave of R&D is targeting synthetic lethality in MYC-overexpressing solid tumors and tau phosphorylation inhibition in neurodegenerative disorders.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutions, Biotech Startups | TNBC, Colorectal Cancer | Selectivity Assay (Need high-purity NUAK1 vs. NUAK2 proteins) |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | Ovarian Cancer, Glioma | Target Ubiquitination (Need USP9X and NUAK1 pathway components) |
| Gene Therapies / RNAi | Oligonucleotide Therapeutics Developers | Alzheimer's Disease, Tauopathies | Knockdown Validation (Need sequence-verified siRNA and Lentivirus) |